These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 2627263)

  • 1. Lymphokine-activated killer (LAK) activity to cultured rat kidney parenchymal components in vitro.
    Nietosvaara Y; Renkonen R; Mattila P; Häyry P
    Transpl Int; 1989 Dec; 2(4):209-13. PubMed ID: 2627263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
    Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
    J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo boosting of lung natural killer and lymphokine-activated killer cell activity by interleukin-2: comparison of systemic, intrapleural and inhalation routes.
    Flexman JP; Manning LS; Robinson BW
    Clin Exp Immunol; 1990 Oct; 82(1):151-6. PubMed ID: 2208789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon-gamma-treated K562 target cells distinguish functional NK cells from lymphokine-activated killer (LAK) cells.
    Powell J; Stone J; Chan WC; Yang ZD; Leatherbury A; Sell KW; Wiktor-Jedrzejczak W; Ahmed-Ansari A
    Cell Immunol; 1989 Feb; 118(2):250-64. PubMed ID: 2491960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma.
    Muralikrishna K; Varalakshmi C; Khar A
    Cytokines Cell Mol Ther; 1997 Mar; 3(1):51-8. PubMed ID: 9287244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lysis of pulmonary fibroblasts by lymphokine (IL-2)-activated killer cells--a mechanism affecting the human lung microenvironment?
    Zambello R; Trentin L; Enthammer C; Cipriani A; Agostini C; Semenzato G
    Clin Exp Immunol; 1996 Aug; 105(2):383-8. PubMed ID: 8706349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphokine-activated killer cells in rats. IV. Developmental relationships among large agranular lymphocytes, large granular lymphocytes, and lymphokine-activated killer cells.
    Maghazachi AA; Vujanovic NL; Herberman RB; Hiserodt JC
    J Immunol; 1988 Apr; 140(8):2846-52. PubMed ID: 3258622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The specificity of lymphokine-activated killer (LAK) cells in vitro: fresh normal murine tissues are resistant to LAK-mediated lysis.
    Lefor AT; Rosenberg SA
    J Surg Res; 1991 Jan; 50(1):15-23. PubMed ID: 1987427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphokine-activated killer cells lyse human renal cancer cell lines and cultured normal kidney cells.
    Miltenburg AM; Meijer-Paape ME; Daha MR; Paul LC
    Immunology; 1988 Apr; 63(4):729-31. PubMed ID: 3259208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibility to lysis of pulmonary alveolar macrophages by human lymphokine-activated killer cells.
    Zambello R; Trentin L; Feruglio C; Bulian P; Masciarelli M; Cipriani A; Agostini C; Semenzato G
    Cancer Res; 1990 Mar; 50(6):1768-73. PubMed ID: 2106387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gelatin sponge model of effector recruitment: tumoricidal activity of adherent and non-adherent lymphokine-activated killer cells after culture in interleukin-2.
    Akporiaye ET; Barbieri CA; Stewart CC; Bender JG
    J Leukoc Biol; 1991 Feb; 49(2):189-96. PubMed ID: 1991999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bovine NK and LAK susceptibility is independent of class I expression on B lymphoblastoid variants.
    Li W; Splitter GA
    Vet Immunol Immunopathol; 1994 Jun; 41(3-4):189-200. PubMed ID: 7941303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
    Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC
    Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
    Colquhoun SD; Economou JS; Shau H; Golub SH
    J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leukoregulin up-regulation of tumor cell sensitivity to natural killer and lymphokine-activated killer cell cytotoxicity.
    Furbert-Harris PM; Evans CH
    Cancer Immunol Immunother; 1989; 30(2):86-91. PubMed ID: 2688871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral effect of lymphokine-activated killer cells: characterization of effector cells mediating prophylaxis.
    Bukowski JF; Yang H; Welsh RM
    J Virol; 1988 Oct; 62(10):3642-8. PubMed ID: 2458485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal allograft rejection: protection of renal tubular epithelial cells from lymphokine activated killer cell mediated lysis by pretreatment with cytokines.
    Kirby JA; Forsythe JL; Simm A; Proud G; Taylor RM
    Nephrol Dial Transplant; 1989; 4(9):824-8. PubMed ID: 2483256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural killer (NK) cell subsets in the mouse. NK-1.1+/LGL-1+ cells restricted to lysing NK targets, whereas NK-1.1+/LGL-1- cells generate lymphokine-activated killer cells.
    Mason LH; Mathieson BJ; Ortaldo JR
    J Immunol; 1990 Jul; 145(2):751-9. PubMed ID: 2365999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD18/CD54(+CD102), CD2/CD58 pathway-independent killing of lymphokine-activated killer (LAK) cells against glioblastoma cell lines T98G and U373MG.
    Komatsu F; Kajiwara M
    Oncol Res; 2000; 12(1):17-24. PubMed ID: 11061342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.